- Presentation With Live Webcast on Thursday, Dec. 3rd at 8:30 a.m. PT / 11:30 a.m. ET -
BEDMINSTER, N.J., Nov. 19, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that it will present at the 8th Annual LD Micro Main Event on December 3, 2015, at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time) at the Luxe Sunset Hotel in Los Angeles, CA.
Jerome D. Jabbour, EVP, Co-Founder and Chief Business Officer, will provide an update on the NIH/NIAID-funded Phase 2a clinical study of the Company’s lead drug candidate MAT2203, an orally-administered, lipid-crystal nano-particle formulation of broad spectrum fungicidal agent amphotericin B. Matinas BioPharma expects to commence dosing in patients with refractory mucocutaneous candidiasis before the end of 2015 and report topline data from this study in 2016. Mr. Jabbour will also discuss the Company’s development plans for MAT2501, an orally-administered, encochleated formulation of the broad spectrum aminoglycoside antibiotic agent amikacin for severe hospital-acquired bacterial infections. Matinas BioPharma is preparing to file an Investigational New Drug (IND) application for MAT2501 with the U.S. Food and Drug Administration before the end of 2015.
A live audio webcast of the presentation will be available on the Company’s website (www.matinasbiopharma.com) in the Investor Relations section of the Events page. The webcast replay be available approximately two hours after the presentation ends and will be accessible for one month.
About LD Micro
LD Micro is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published reports on select companies throughout the year. The annual Main Event micro-cap conference was designed to highlight and showcase the next generation of great companies to private and institutional investors, as well as to analysts, bloggers, and the media. The firm also hosts the LD Micro Invitational. LD Micro is a non-registered investment advisor.
About Matinas BioPharma
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections. The Company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. The Company's lead drug candidate is MAT2203, an orally-administered, encochleated formulation of amphotericin B (a broad spectrum fungicidal agent). The Company also intends to file an Investigational New Drug (IND) application for MAT2501, which is an orally-administered, encochleated formulation of amikacin (a broad spectrum aminoglycoside antibiotic agent) for gram-negative and intracellular bacterial infections. In addition, the Company is exploring development and partnership options for MAT9001, a prescription-only omega-3 fatty acid-based composition under development for hypertriglyceridemia, which has shown superiority versus Vascepa® (icosapent ethyl) in reducing serum triglycerides, Total- and Non-HDL-Cholesterol, apolipoproteins and PCSK9 levels.
The Company's lead anti-infective product candidates, MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulation technology.
BEDMINSTER, N.J., Nov. 19, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that it will present at the 8th Annual LD Micro Main Event on December 3, 2015, at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time) at the Luxe Sunset Hotel in Los Angeles, CA.
Jerome D. Jabbour, EVP, Co-Founder and Chief Business Officer, will provide an update on the NIH/NIAID-funded Phase 2a clinical study of the Company’s lead drug candidate MAT2203, an orally-administered, lipid-crystal nano-particle formulation of broad spectrum fungicidal agent amphotericin B. Matinas BioPharma expects to commence dosing in patients with refractory mucocutaneous candidiasis before the end of 2015 and report topline data from this study in 2016. Mr. Jabbour will also discuss the Company’s development plans for MAT2501, an orally-administered, encochleated formulation of the broad spectrum aminoglycoside antibiotic agent amikacin for severe hospital-acquired bacterial infections. Matinas BioPharma is preparing to file an Investigational New Drug (IND) application for MAT2501 with the U.S. Food and Drug Administration before the end of 2015.
A live audio webcast of the presentation will be available on the Company’s website (www.matinasbiopharma.com) in the Investor Relations section of the Events page. The webcast replay be available approximately two hours after the presentation ends and will be accessible for one month.
About LD Micro
LD Micro is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published reports on select companies throughout the year. The annual Main Event micro-cap conference was designed to highlight and showcase the next generation of great companies to private and institutional investors, as well as to analysts, bloggers, and the media. The firm also hosts the LD Micro Invitational. LD Micro is a non-registered investment advisor.
About Matinas BioPharma
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections. The Company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. The Company's lead drug candidate is MAT2203, an orally-administered, encochleated formulation of amphotericin B (a broad spectrum fungicidal agent). The Company also intends to file an Investigational New Drug (IND) application for MAT2501, which is an orally-administered, encochleated formulation of amikacin (a broad spectrum aminoglycoside antibiotic agent) for gram-negative and intracellular bacterial infections. In addition, the Company is exploring development and partnership options for MAT9001, a prescription-only omega-3 fatty acid-based composition under development for hypertriglyceridemia, which has shown superiority versus Vascepa® (icosapent ethyl) in reducing serum triglycerides, Total- and Non-HDL-Cholesterol, apolipoproteins and PCSK9 levels.
The Company's lead anti-infective product candidates, MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulation technology.
